[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Cg Oncology Inc (CGON)

Cg Oncology Inc (CGON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,724,230
  • Shares Outstanding, K 88,640
  • Annual Sales, $ 4,040 K
  • Annual Income, $ -161,000 K
  • EBIT $ -253 M
  • EBITDA $ -252 M
  • 60-Month Beta 0.23
  • Price/Sales 1,649.06
  • Price/Cash Flow N/A
  • Price/Book 6.37

Options Overview Details

View History
  • Implied Volatility 92.77% (-1.73%)
  • Historical Volatility 47.97%
  • IV Percentile 69%
  • IV Rank 54.26%
  • IV High 134.44% on 06/17/26
  • IV Low 43.34% on 08/26/26
  • Expected Move (DTE 16) 4.85 (6.39%)
  • Put/Call Vol Ratio 0.61
  • Today's Volume 108
  • Volume Avg (30-Day) 1,142
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 17,319
  • Open Int (30-Day) 20,912
  • Expected Range 71.02 to 80.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.86
  • Number of Estimates 7
  • High Estimate $-0.66
  • Low Estimate $-0.96
  • Prior Year $-0.57
  • Growth Rate Est. (year over year) -50.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
68.08 +11.43%
on 08/03/26
80.97 -6.31%
on 08/19/26
+4.67 (+6.56%)
since 07/31/26
3-Month
53.21 +42.57%
on 06/08/26
80.97 -6.31%
on 08/19/26
+16.63 (+28.08%)
since 06/01/26
52-Week
26.25 +189.05%
on 09/02/25
80.97 -6.31%
on 08/19/26
+49.04 (+182.85%)
since 08/29/25

Most Recent Stories

More News
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm

NEW YORK , Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. ( NASDAQ...

CGON : 75.86 (+0.93%)
Inflation Numbers Due Next Week

Monday U.S. Featured Earnings Simon Property Group, Inc. (NYSE:SPG) (Q2) EPS of $3.18, ...

AMAT : 441.85 (-3.61%)
CSCO : 109.74 (-0.68%)
COHR : 272.03 (-2.09%)
SPG : 211.87 (-0.21%)
CAH : 239.35 (+2.02%)
BN : 39.74 (-3.59%)
LITE : 868.95 (-5.01%)
IMMX : 14.01 (-0.14%)
NTES : 120.07 (-1.40%)
SE : 112.65 (-0.73%)
FERG : 218.91 (-2.49%)
ALC : 71.75 (-0.43%)
CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates

PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-term BLA completion for HR BCG-unresponsive NMIBC expected...

CGON : 75.86 (+0.93%)
CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates

DALLAS, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the second quarter ended June 30, 2026, and provided business updates.

CGON : 75.86 (+0.93%)
CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology

DALLAS, July 27, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced the publication of results from the pivotal Phase 3 BOND-003 Cohort C trial evaluating cretostimogene grenadenorepvec...

CGON : 75.86 (+0.93%)
CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology

Data reinforce durable responses, bladder preservation, low rate of disease progression, and favorable safety and tolerability in patients with high-risk,...

CGON : 75.86 (+0.93%)
CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push

CG Oncology (NASDAQ:CGON) is focused on advancing cretostimogene, an oncolytic immunotherapy for non-muscle invasive bladder cancer, Chief Executive Officer Arthur Kuan said during a discussion at the...

CGON : 75.86 (+0.93%)
CG Oncology to Present at Upcoming Investor Conferences in June

DALLAS, May 28, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations...

CGON : 75.86 (+0.93%)
CG Oncology to Present at Upcoming Investor Conferences in June

DALLAS, May 28, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive...

CGON : 75.86 (+0.93%)
CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference

CG Oncology (NASDAQ:CGON) executives used an RBC Capital Markets fireside chat to outline recent clinical data for cretostimogene, the company’s investigational therapy for non-muscle invasive bladder...

CGON : 75.86 (+0.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology is based in IRVINE, Calif.

See More

Key Turning Points

3rd Resistance Point 78.71
2nd Resistance Point 77.47
1st Resistance Point 76.67
Last Price 75.86
1st Support Level 74.63
2nd Support Level 73.39
3rd Support Level 72.58

See More

52-Week High 80.97
Last Price 75.86
Fibonacci 61.8% 60.07
Fibonacci 50% 53.61
Fibonacci 38.2% 47.15
52-Week Low 26.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.